Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769375 | 1.00 | P2RX3 (0.46) | P2RX3HRH3PIM1KCNH2EPHX2 | |
| SCHEMBL29523978 | 0.87 | HRH3 (0.53) | P2RX3HRH3PIM1KCNH2EPHX2 | |
| SCHEMBL27483408 | 0.86 | P2RX3 (0.57) | P2RX3HRH3PIM1KCNH2 | |
| SCHEMBL8342318 | 0.86 | P2RX3 (0.57) | P2RX3HRH3PIM1KCNH2 | |
| SCHEMBL29523531 | 0.86 | HRH3 (0.52) | P2RX3HRH3PIM1KCNH2EPHX2 | |
| SCHEMBL12442660 | 0.86 | HRH3 (0.52) | P2RX3HRH3PIM1KCNH2EPHX2 | |
| SCHEMBL23260557 | 0.86 | HRH3 (0.50) | P2RX3HRH3PIM1 | |
| SCHEMBL3961763 | 0.86 | HRH3 (0.50) | P2RX3HRH3PIM1 | |
| SCHEMBL951361 | 0.86 | HRH3 (0.50) | P2RX3HRH3PIM1 | |
| SCHEMBL950955 | 0.86 | HRH3 (0.50) | P2RX3HRH3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710064-B2 | FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES | BRISTOL-MYERS SQUIBB CO. | 2004-03-23 | — | — | US | disclosed |
| EP-1339718-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | P2RX3 1304/4885HRH3 8/4885PIM1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.